OBJECTIVE: To study whether body mass index (BMI) is different in girls with Turner syndrome (TS) compared to normal girls, and whether BMI in TS is affected by growth hormone (GH) treatment. DESIGN: A retrospective cross-sectional study. SUBJECTS: 2468 girls with TS enrolled in the National Cooperative Group Study (NCGS), a collaborative surveillance study for assessing GH-treated children. MEASUREMENTS: BMI and BMI standard deviation score (BMI SDS) at baseline and during GH treatment were computed from height and weight data. RESULTS: BMI in TS patients increases with age as expected. However, BMI SDS increased starting at about age 9 y. A similar pattern of increase in BMI SDS was observed after each year of GH treatment for up to 4 y, but GH treatment did not change the magnitude of increase. BMI and BMI SDS curves before and during GH treatment were essentially superimposable. CONCLUSION: These ®ndings suggest that mechanisms speci®c for TS are responsible for the age-related increase in BMI SDS. This increase was unaffected by GH treatment.
Introduction
Short stature is one of the most common phenotypic features of Turner syndrome (TS). 1 Growth hormone (GH) alone or in combination with oxandrolone can increase adult height in TS, and GH treatment is now the standard of care for girls with TS in many countries. 1 ± 4 Girls with TS are thought to be prone to gain excessive weight, which may be a risk factor for developing diabetes and cardiovascular disease in adult life. 5 ± 7 For this reason, we were interested in studying the effect of GH treatment on body mass index (BMI) in order to determine if GH in¯uences body composition in ways unrelated to linear growth. We chose to study BMI because it has been validated as an indicator of obesity in children and is widely used for this purpose. 8, 9 Furthermore, height and weight, from which the BMI could be computed, were available to us.
Data from the National Cooperative Growth Study (NCGS) 1 were analyzed to determine whether there would be changes in BMI in TS girls relative to normal girls during GH treatment.
Methods

Description of the patients
The NCGS was established in 1985 to monitor the safety and effectiveness of Genentech GH products. The methods of subject enrollment and data collection have been described elsewhere. 1 As of 30 June, 1998, 272 children had been enrolled in the NCGS database. There were 3114 girls with TS. This analysis is con®ned to the 2468 girls who had not been treated with GH before enrolling in NCGS and who remained prepubertal throughout the 4 y of observation. Height measurements were performed at the participating centers using a Harpenden stadiometer or other wallmounted device as speci®ed in the NCGS protocol. Weight measurements were carried out using a balance beam. BMI was calculated as the weight in kilograms divided by the height in meters squared. BMI standard deviation score (SDS) was calculated using data from the First National Health and Nutrition Examination Study (NHANES). 11 
Analysis
Statistical analyses and graphics were carried out using`Splus' for programming. 12 Both BMI SDS and BMI values were plotted against age at enrollment and age after the 1st, 2nd, 3rd and 4th year of GH treatment. Smoothed curves (lowess) were plotted for the median BMI for age and the mean BMI SDS.
Results
When BMI at enrollment was plotted against age at enrollment in TS ( Figure 1A) , there was an increase in BMI with age similar to that observed in the normal girls.
11 Median BMI was unaffected by GH treatment for a period of up to 4 y. This is indicated by the fact that the curves for BMI before and during GH treatment are superimposable ( Figure 1B ). When BMI SDS at enrollment was plotted against age, the mean BMI SDS for younger girls was close to zero with most values between plus and minus two standard deviations, indicating that BMI is relatively normal in young TS girls. At about age 9 ± 10 y, there was a progressive increase in the mean BMI SDS ( Figure  2A ), indicating that TS girls have increased BMI relative to unaffected girls at these ages. After age 12 y, the mean BMI SDS curve was relatively¯at, but the mean BMI SDS remained greater than the values for younger girls. Similar age-related increases in BMI SDS occurred after GH treatment. However, the curves of BMI SDS vs age were almost superimposable, indicating no effect of GH on BMI SDS ( Figure 2B ).
Discussion
Since percentiles and smoothed percentile curves have become available both in the US and in the UK, studies have supported the use of BMI as an index of adiposity in children. 8,9,13 ± 15 It has also been validated using dual X-ray absorptiometry as the standard 16 and recommended for assessing obesity by an expert panel. 17 A high BMI has added signi®-cance in childhood since it predicts adiposity in adulthood. 18 However the signi®cance of BMI¯uc-tuations in children with altered phenotypes affecting body proportions is unclear. This study provides information on a large number of girls with TS and a wide range of BMI values, showing that weight for stature indices such as BMI may lack speci®city as an index of body fat. 19 Nevertheless analysis of a large set of data provides evidence on whether there is a tendency for girls with TS to become obese and serves as a possible guide to further studies on body composition analysis using other methods. 19 Our results con®rm previous observations that older girls with TS are relatively overweight as a group. 6 Cross-sectional analysis of the TS girls before GH treatment showed that an increase in BMI SDS occurred at age 9 ± 10 y. Because computation of the BMI SDS was based on normal girls in NHANES I, the increase in BMI SDS may re¯ect an observation speci®c for TS. A BMI SDS based on normal girls as the standard provided a way to contrast girls with TS, nevertheless the normal girls in the NHANES study would have started puberty within a normal age range, whereas TS girls did not. Since normal girls increase their adiposity during pubertal development, 20, 21 the fact that TS girls underwent a relatively excessive gain in BMI represented by the SDS is all the more signi®cant.
Since the change in BMI SDS with age was similar after each of the ®rst 4 y of GH treatment, there was no recognizable effect of GH on BMI SDS. Our results are consistent with Corel et al, 22 who reported that the leaner TS girls treated with GH had an increase in BMI SDS. Interestingly, this group also observed that those with a BMI SDS greater than 2 at baseline had an initial decrease consistent with an initial lipolytic effect due to growth hormone. Also, the patients in this multi-national study were mostly between ages 9 and 13 y when they began GH. This is the age range where we found an increase in BMI SDS that occurred both with and without GH treatment. Thus, we suggest that the changes in BMI SDS reported in TS girls were not due to GH treatment but merely the re¯ection of a process that occurs in TS girls as they grow older. This suggestion is supported by a study of heights and weights in TS girls from the Netherlands, Denmark and Sweden. 23 In this study, TS girls showed a disproportionate increase in weight at adolescent ages. Although the data were not analyzed by age, the shift in weight for height percentiles was found for heights greater than 120 cm. This is the approximate height of 9-y-old girls with TS. Thus our results con®rm and complement those of Rongen-Westerlaken et al 23 and suggest a disproportionate increase in adiposity in TS patients in the second decade of life. These data do not support a role for GH in the process.
We propose three possible explanations for the agerelated increase in BMI SDS in TS. These could also act in combination. First, the onset of adrenarche without gonadal changes of puberty could result in the absence of ovarian steroids to balance increasing levels of adrenal androgens. 24 This hormonal imbalance could then result in the observed changes in body composition. Second, the increase in weight relative to height could be a compensatory phenomenon by which the girls with TS have a tendency to achieve à critical weight' required for the onset of menarche as proposed by Frisch and McArthur. 25 When menarche fails to occur weight gain may continue past a set point normally regulated by the onset of puberty. Third, decreased limb relative to trunk growth results in the short stocky physique and an increased weight for height characteristic of girls with TS. 26 The appearance of these characteristics may be re¯ected by the upward swing in the BMI SDS at age 9 y. A relative increase in somatic tissue in TS is supported by the ®nding that skin-fold thickness is less than in children with similar weight for height. 4 Figure 2 (A) BMI SDS at enrollment was plotted against age for individual girls with TS. The smoothed curve shows the mean BMI SDS. (B) Smoothed curves for mean BMI SDS vs age for Turner girls before GH (ÐÐ), and after 1 ( Á Á Á ), 2 (---), 3 ( ± ± ± ), and 4 ( Ð Ð Ð ) y of GH treatment. Note that the curves are essentially superimposable.
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The age-related increase in BMI SDS appears to be unique for TS and is unaffected by GH treatment. This ®nding supports the development of more speci®c studies to de®ne what changes in body composition may occur and the mechanisms responsible.
